Jasper Therapeutics (JSPR) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Fiserv president resigns, interim leaders named for financial unit
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Jasper Therapeutics (JSPR) PT Lowered to $68 at RBC Capital
August 14, 2024 6:25 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Jasper Therapeutics (NASDAQ: JSPR) to $68.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "JSPR provided the updated timeline for briq's initial BEACON readout (CSU), now confirmed for 4Q24... More
